<xzoap class="kqeyb"></xzoap>

圣淘沙名胜世界

Be the most trusted biotech company

2021-10-12

Henlius Announces Dr. Jean-Michel Gries as President of Hengenix
2021-09-30

First Patient Dosed in Phase 2 Clinical Trial of HLX22 Combo Therapy in Patients with HER2-positive Gastric Cancer
2021-09-28

Hepatocellular Carcinoma Phase 2 Clinical Study Results of a Novel anti-PD-1 mAb Serplulimab has been Selected for the Innovation Session at 2021 CSCO
2021-09-26

Henlius Presents Results from Phase 2 Clinical Study of Its Novel anti-PD-1 mAb Serplulimab in Patients with Advanced Cervical Cancer at 2021 CSCO
2021-09-17

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
2021-08-18

Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
2021-08-05

Henlius Entered into a Collaboration with Promega to Develop the Companion Diagnostic Kit for Henlius' Serplulimab MSI-H Solid Tumours Indication
2021-07-19

First Patient Dosed in Phase 1 Clinical Trial of Henlius Bevacizumab HLX04-O
2021-06-01

Henlius Received IND Approval for Its Novel Anti-CD73 mAb HLX23 from US FDA